Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Jones Trading

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by equities research analysts at Jones Trading from a “buy” rating to a “hold” rating in a research report issued on Tuesday, MarketBeat reports.

NTLA has been the subject of several other research reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $5.00 price objective (down previously from $12.00) on shares of Intellia Therapeutics in a research note on Friday, November 7th. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. HC Wainwright dropped their price target on shares of Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Monday. Wedbush reduced their price objective on shares of Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Finally, Oppenheimer set a $27.00 target price on Intellia Therapeutics in a research report on Friday, November 7th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Hold” and a consensus price target of $18.25.

Intellia Therapeutics Stock Down 6.8%

NASDAQ NTLA opened at $9.49 on Tuesday. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -2.22 and a beta of 2.44. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25. The business’s fifty day moving average is $17.09 and its 200 day moving average is $12.54.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.12 million. During the same quarter in the prior year, the firm earned ($1.34) EPS. The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. On average, research analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intellia Therapeutics news, Director William J. Chase purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was purchased at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the acquisition, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the transaction, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This trade represents a 3.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently added to or reduced their stakes in NTLA. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth approximately $26,000. Blue Bell Private Wealth Management LLC bought a new position in Intellia Therapeutics during the third quarter worth $30,000. Whipplewood Advisors LLC grew its holdings in Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after purchasing an additional 3,447 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after purchasing an additional 1,655 shares in the last quarter. Finally, Harbour Investments Inc. increased its stake in Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after purchasing an additional 2,264 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.